Safety and efficacy of switching to biosimilars in IBD

被引：0
|
作者：
Isobel Leake
机构：
来源：
Nature Reviews Gastroenterology & Hepatology | 2016年 / 13卷 / 6期
关键词：
D O I：
10.1038/nrgastro.2016.79
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：314 / 314
相关论文
共 50 条
  • [1] The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
    Barbier, Liese
    Ebbers, Hans C.
    Declerck, Paul
    Simoens, Steven
    Vulto, Arnold G.
    Huys, Isabelle
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (04) : 734 - 755
  • [2] Safety and efficacy of biosimilars in oncology
    Schellekens, Huub
    Smolen, Josef S.
    Dicato, Mario
    Rifkin, Robert M.
    LANCET ONCOLOGY, 2016, 17 (11): : E502 - E509
  • [3] Biosimilars in IBD
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (01): : 14 - 14
  • [4] Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
    Maccora, Ilaria
    Simonini, Gabriele
    Bettiol, Alessandra
    Pagnini, Ilaria
    Lombardi, Niccolo
    Maniscalco, Valerio
    Crescioli, Giada
    Marrani, Edoardo
    Bonaiuti, Roberto
    Mastrolia, Maria Vincenza
    Ravaldi, Claudia
    Vannacci, Alfredo
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [5] MAKING THE CHANGE: SWITCHING TO INFLIXIMAB BIOSIMILARS FOR IBD AT NORTH BRISTOL NHS TRUST
    Chung, L.
    Arnold, B.
    Johnson, R.
    Lockett, M. J.
    GUT, 2016, 65 : A22 - A23
  • [6] A Survey Among IBD Patients Following Switching From Originator Infliximab to Its Biosimilars
    Doan, Anh Trinh
    Johnson, Christopher
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S867 - S867
  • [7] Biosimilars in IBD: hope or expectation?
    Gecse, Krisztina B.
    Khanna, Reena
    van den Brink, Gijs R.
    Ponsioen, Cyriel Y.
    Lowenberg, Mark
    Jairath, Vipul
    Travis, Simon P. L.
    Sandborn, William J.
    Feagan, Brian G.
    D'Haens, Geert R. A. M.
    GUT, 2013, 62 (06) : 803 - 807
  • [8] BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN IBD
    Barrett, Rachael
    Siakavellos, Spyros
    Plevris, Nikolas
    Gauci, Julia
    Lucaciu, Laura
    Arnott, Ian
    Merchant, Lynne
    Jones, Gareth-Rhys
    Derikx, Lauranne
    Lees, Charles
    GUT, 2021, 70 : A101 - A101
  • [9] The Great Debate With IBD Biosimilars
    Panaccione, Remo
    CROHNS & COLITIS 360, 2021, 3 (03)
  • [10] Safety of switching between rituximab biosimilars in onco-hematology
    Silvana A. M. Urru
    Stefania Spila Alegiani
    Anna Guella
    Giuseppe Traversa
    Annalisa Campomori
    Scientific Reports, 11
12345